ASCLETIS-B (1672.HK)
- Previous Close
6.670 - Open
6.800 - Bid 6.610 x --
- Ask 6.650 x --
- Day's Range
6.590 - 7.250 - 52 Week Range
0.760 - 9.280 - Volume
4,389,000 - Avg. Volume
7,492,828 - Market Cap (intraday)
6.362B - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.320 - Earnings Date Mar 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.93
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
www.ascletis.comRecent News: 1672.HK
View MorePerformance Overview: 1672.HK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1672.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1672.HK
View MoreValuation Measures
Market Cap
6.42B
Enterprise Value
4.34B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.85k
Price/Book (mrq)
3.04
Enterprise Value/Revenue
3.15k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.96%
Return on Equity (ttm)
-13.97%
Revenue (ttm)
1.28M
Net Income Avi to Common (ttm)
-300.94M
Diluted EPS (ttm)
-0.320
Balance Sheet and Cash Flow
Total Cash (mrq)
1.95B
Total Debt/Equity (mrq)
0.39%
Levered Free Cash Flow (ttm)
-208.35M